Discover How Wegovy Weight Loss Drug Reduces Heart Attack Risk in Groundbreaking Trial
Novo Nordisk’s obesity drug, Wegovy, has been hailed for its milestone findings in a landmark cardiovascular trial that demonstrates its ability to reduce the risk of heart attacks. The trial, called Select, showcased how Wegovy not only leads to weight loss but also significantly reduces the likelihood of major heart problems such as heart attacks, …